Literature DB >> 31171738

Brain targeted delivery of anticancer drugs: prospective approach using solid lipid nanoparticles.

Anupriya Anand1, Abimanyu Sugumaran2, Damodharan Narayanasamy1.   

Abstract

A brain tumour is amongst most devastating and challenging condition to overcome with suitable treatment as the drug has to cross the blood-brain barrier (BBB) with several physiological barriers like opsonisation by the reticuloendothelial system. Presently various techniques such as surgical, chemotherapeutic agents, and radiotherapy techniques have performed to extend the lifespan of patients diagnosed with glioblastoma, which did not maximise the overall survival of patients with a tumour. Nanotechnology is relied upon to diminish the requirement for intrusive methods for conveyance of therapeutics to the central nervous system. Colloidal nanocarriers sizing range 1-1000 nm have been utilised to cross BBB delivers the drug at cell levels with enhanced bioavailability and reduced toxicity. However, solid lipid nanoparticles (SLNs) are considered a highly flexible carrier for more successful remedially in brain tumour. The treatment of a brain tumour via SLNs is gaining greater potency due to its inimitable size and lipidic nature. This review focuses and represents the current strategies of SLNs in the brain tumour treatment with appropriate techniques adopted are highlighted. Based on this review, the authors concluded that SLNs embrace exclusive promising lipidic nanocarrier that could be utilised to target a brain tumour effectively.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31171738      PMCID: PMC8676006          DOI: 10.1049/iet-nbt.2018.5322

Source DB:  PubMed          Journal:  IET Nanobiotechnol        ISSN: 1751-8741            Impact factor:   1.847


  71 in total

Review 1.  Transport of drugs from the nasal cavity to the central nervous system.

Authors:  L Illum
Journal:  Eur J Pharm Sci       Date:  2000-07       Impact factor: 4.384

Review 2.  Nasal drug delivery--possibilities, problems and solutions.

Authors:  Lisbeth Illum
Journal:  J Control Release       Date:  2003-02-21       Impact factor: 9.776

Review 3.  Dendritic cell vaccination in patients with malignant gliomas: current status and future directions.

Authors:  Steven de Vleeschouwer; Marion Rapp; Rüdiger V Sorg; Hans-Jakob Steiger; Walter Stummer; Stefaan van Gool; Michael Sabel
Journal:  Neurosurgery       Date:  2006-11       Impact factor: 4.654

4.  Tumor specific delivery and therapy by double-targeted nanostructured lipid carriers with anti-VEGFR-2 antibody.

Authors:  Donghua Liu; Fengxi Liu; Zhihong Liu; Lili Wang; Na Zhang
Journal:  Mol Pharm       Date:  2011-10-26       Impact factor: 4.939

5.  Positive-charged solid lipid nanoparticles as paclitaxel drug delivery system in glioblastoma treatment.

Authors:  Daniela Chirio; Marina Gallarate; Elena Peira; Luigi Battaglia; Elisabetta Muntoni; Chiara Riganti; Elena Biasibetti; Maria Teresa Capucchio; Alberto Valazza; Pierpaolo Panciani; Michele Lanotte; Laura Annovazzi; Valentina Caldera; Marta Mellai; Gaetano Filice; Silvia Corona; Davide Schiffer
Journal:  Eur J Pharm Biopharm       Date:  2014-11       Impact factor: 5.571

6.  Delivering etoposide to the brain using catanionic solid lipid nanoparticles with surface 5-HT-moduline.

Authors:  Yung-Chih Kuo; Tsu-Yu Hong
Journal:  Int J Pharm       Date:  2014-02-10       Impact factor: 5.875

7.  Doxorubicin encapsulated in liposomes containing surface-bound polyethylene glycol: pharmacokinetics, tumor localization, and safety in patients with AIDS-related Kaposi's sarcoma.

Authors:  D W Northfelt; F J Martin; P Working; P A Volberding; J Russell; M Newman; M A Amantea; L D Kaplan
Journal:  J Clin Pharmacol       Date:  1996-01       Impact factor: 3.126

8.  Conjugation of melanotransferrin antibody on solid lipid nanoparticles for mediating brain cancer malignancy.

Authors:  Yung-Chih Kuo; In-Wei Chao
Journal:  Biotechnol Prog       Date:  2015-12-31

Review 9.  Agomelatine: a preliminary review of a new antidepressant.

Authors:  Michael Zupancic; Christian Guilleminault
Journal:  CNS Drugs       Date:  2006       Impact factor: 5.749

10.  A unique carrier for delivery of therapeutic compounds beyond the blood-brain barrier.

Authors:  Delara Karkan; Cheryl Pfeifer; Timothy Z Vitalis; Gavin Arthur; Maki Ujiie; Qingqi Chen; Sam Tsai; Gerrasimo Koliatis; Reinhard Gabathuler; Wilfred A Jefferies
Journal:  PLoS One       Date:  2008-06-25       Impact factor: 3.240

View more
  2 in total

Review 1.  Combination of cell-penetrating peptides with nanomaterials for the potential therapeutics of central nervous system disorders: a review.

Authors:  Ying Zhang; Pan Guo; Zhe Ma; Peng Lu; Dereje Kebebe; Zhidong Liu
Journal:  J Nanobiotechnology       Date:  2021-08-23       Impact factor: 10.435

Review 2.  Nanocarriers Call the Last Shot in the Treatment of Brain Cancers.

Authors:  Amin Mehrabian; Mohammad Mashreghi; Saba Dadpour; Ali Badiee; Leila Arabi; Seyedeh Hoda Alavizadeh; Seyedeh Alia Moosavian; Mahmoud Reza Jaafari
Journal:  Technol Cancer Res Treat       Date:  2022 Jan-Dec
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.